Rennova Health Partners With Certainty Health to Deliver Direct to Consumer Molecular Testing for Psychiatric Disorders

WEST PALM BEACH, FL -- (Marketwired) -- 06/27/17 -- Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions for healthcare providers, announced today an agreement between its subsidiary Advanced Molecular Services Group, Inc. (AMS Group) and Certainty Health, LLC, a pioneer in cloud-based mobile applications for patient-focused health information. The partnership will develop next generation smartphone tools to enable patients, families, and their healthcare teams to confidently assess the importance of a patients' genetic background in treatment decisions for various psychiatric diseases.

"We look forward to working with Rennova Health to expand a mobile precision medicine platform to immediately address the unmet needs of patients and their caregivers for relevant molecular information impacting psychiatry today," stated Dr. Chris Yoo, President and COO of Certainty Health. "Rennova's incredibly rich and growing databases of pharmacogenomic drug metabolism data represents over a decade of real-world diagnostic results for multiple diseases and together with Rennova, we will democratize access to this knowledge for the benefit of patients."

Under the terms of the agreement, Rennova will market consumer-facing genetic tests developed by its AMS Group using the Certainty Health brand. The first products to be offered through the mobile platform will include tests that can determine how an individual might respond to a number of pharmaceutical drugs used to treat psychiatric disorders. In the U.S. according to NAMI, the National Alliance on Mental Illness, 43.8 million people are being treated for psychiatric issues and an estimated 66% more people go untreated, according to the World Health Organization. The collaboration will deliver test results for these patients, physicians, and other stakeholders in the circle of care team to increase the chances that the right drug will be chosen for the right patient in the right amount.

AMS Group projects general availability of the platform and online ordering of its molecular tests by the fourth quarter of 2017. The group's proprietary technology combines patented laboratory testing results with artificial intelligence interpretation to provide treatment options for patients and their physicians.

"Precision medicine is great science, but still too expensive for the average family. Patients and their families need access to advances in diagnostic technologies and interpretation. Rennova's AMS Group is bringing its patented pharmacogenomic platform directly to consumers," said Dr. Scott Jenkins, CEO of Rennova's Advanced Molecular Services Group. "Today the cost of and access to these tests is prohibitive to the people who need it most. Modern ecommerce and mobile tools will bring immediate access to these life-changing diagnostics and tools to everyone."

About Certainty Health, LLC

Headquartered in Scottsdale, Arizona, Certainty Health, LLC provides mobile device applications for patients, the circle of care, and physicians who need access to the latest, trusted information about complex diseases and how to treat them. Certainty Health has developed a proprietary collaboration platform based on intelligent group clustering algorithms originally used in the financial industry to match investors with those seeking funding. Led by industry veterans from the information technology, biomedical research, and Silicon Valley markets, Certainty Health is transforming the way we collect, communicate, and collaborate over medical knowledge for every patient to have access to the most effective treatments for their individual disease. For more information, please visit http://www.certaintyhealth.com/

About Rennova Health, Inc.

Rennova provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcomes. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information, please visit www.rennovahealth.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company's most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Contacts:
Rennova Health
Sebastien Sainsbury
561-666-9818
ssainsbury@rennovahealth.com

Investors
LHA
Kim Golodetz
212-838-3777
Kgolodetz@lhai.com
or
Bruce Voss
310-691-7100
Bvoss@lhai.com

Source: Rennova Health, Inc.

Released June 27, 2017